“Young people who inject drugs (PWID) who undergo opioid agonist maintenance therapy with methadone or buprenorphine have more than a 60% reduced risk of acquiring hepatitis C virus (HCV) over time compared to those with no substance use treatment, according to a study presented on Monday at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting in Boston. Findings were also published in the October 27 edition of JAMA Internal Medicine.
Kimberly Page from the University of New Mexico Health Sciences Center, Judith Tsui from Boston University School of Medicine and colleagues evaluated whether opioid agonist therapy was associated with a lower incidence of HCV infection among young adult drug injectors, who are vulnerable to infection soon after they start injecting.
The study compared people who underwent various types of substance use treatment within the past three months: opioid agonist maintenance therapy, detoxification using an opioid agonist (without ongoing maintenance therapy), non-opioid agonist forms of treatment (such as 12-step programmes or counselling) or no treatment.
Source: AidsMap.com – November 11, 2014